Navigation Links
Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
Date:10/2/2013

MONTREAL y EMERYVILLE, California, 2 de octubre de 2013 /PRNewswire-HISPANIC PR WIRE/ -- Adamas Pharmaceuticals, Inc. presentó hoy resultados positivos de la prueba clínica EASED™ Fase 2/3 de ADS-5102 en el Congreso Mundial del Parkinson.  ADS-5102 es la formulación patentada de cápsula de acción prolongada de amantadina HCl de Adamas en desarrollo para el tratamiento de la disquinesia inducida por levodopa (LID por sus siglas en inglés) en pacientes de la enfermedad de Parkinson (PD por sus siglas en inglés).  ADS-5102 alcanzó su punto final primario en la prueba clínica de Fase 2/3 y demostró mejoras estadísticamente significativas en varias evaluaciones claves de la LID.

(Logo:  http://photos.prnewswire.com/prnh/20130618/LA33709LOGO)

"Estamos sumamente complacidos con los resultados positivos logrados en nuestra prueba EASED Fase 2/3, y con la magnitud del cambio en el período de respuesta a los medicamentos sin disquinesia molesta en pacientes de Parkinson que padecen de LID.  La disquinesia inducida por levodopa es uno de los retos más difíciles que afrontan los pacientes de PD, y no hay tratamientos con fármacos aprobados por la FDA disponibles", dijo Gregory T. Went, Ph.D., director ejecutivo de Adamas. "ADS-5102 redujo tanto la duración como la severidad de la disquinesia en pacientes de PD con significación estadística, proporcionando un promedio de 11.5 horas durante el día de período de respuesta a los medicamentos sin disquinesia molesta, en comparación con 8 horas con placebo.  Los alentadores datos de esta prueba indican que ADS-5102 tiene el potencial de ejercer un impacto positivo en la vida de los pacientes de la PD y estamos avanza
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
4. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
8. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
11. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... Aug. 27, 2015 Biosimilars are not ... the U.S. Food and Drug Administration (FDA) for ... in its draft guidance issued today. The FDA,s ... proposes distinguishable names, calling for biological products to ... suffix. This proposal reflects the agency,s thinking that ...
(Date:8/27/2015)... , August 27, 2015 According to ... (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, ... Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling Market ... 411.5 Million in 2015, at a CAGR of 11.4 % from ... ma rket data T ables and ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Failed to Reach Statistical ... ... /PRNewswire-,FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR ) and its,wholly- ... pivotal trials of OvaRex(R) MAb for the,treatment of advanced ovarian cancer. ...
... Cancer Patients, ROCKVILLE, Md., Dec. 4 ... company developing,therapeutics for the treatment of cancer and ... multi-center Phase 2 clinical trial with,MKC-1 in patients ... study will be to determine the antitumor activity ...
Cached Medicine Technology:Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 2Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 3Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 4EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer 2EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer 3EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer 4
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced the ... this summer at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... inventors from Miller Place, N.Y. "I specialize in manual therapy, and my invention ... it can be used for additional muscle dysfunction throughout the body." , They ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... ... 2015 , ... Vascular Health Sciences announced today that an ... HP, and that all claims and counterclaims have been irrevocably dismissed. , In ... the United States District Court for the Southern District of Texas for breach ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... MADISON - For the millions of Americans whose vision is ... lowly neural progenitor// cell may be riding to the rescue. ... derived from human fetal stem cells have been shown to ... to the kinds of diseases that afflict humans. The new ...
... Diabetes and high blood pressure, two conditions rooted in ... than race alone in determining// who is mostly likely ... from cardiologists at Johns Hopkins. Each year, nearly 300,000 ... ,Experts say that racial disparities have long been known ...
... lawmakers Monday it could be a decade or more before ... drugs // in the way the agency approves knockoffs of ... Janet Woodcock's testimony could benefit companies such as Amgen Inc. ... the U.S. for their products, some of the most complex ...
... blood thinner, one of the first signs the drug is ... and bruising,// an inconvenient side effect of preventing the blood ... stroke. While potentially life-saving, the drugs can also pose a ... of blood levels. ,So when he didn’t see ...
... disease causing tennis-ball-size ulcers so painful that victims feel ... than two years// become the second illness after smallpox ... and other preventive methods, the United Nations health agency ... of years of effort by local and international groups ...
... secretary said that computer based therapy will be available ... will be available to all patients in England from ... Beating the blues have been designed as therapies for ... warned that computer aided programs may not be suitable ...
Cached Medicine News:Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Who Gets Heart Failure? Race Takes Back Seat to Diabetes and High Blood Pressure 2Health News:Who Gets Heart Failure? Race Takes Back Seat to Diabetes and High Blood Pressure 3Health News:FDA Cites Challenges of Generic Biotech 2Health News:New Blood Thinner May Work Without Bleeding Risk 2Health News:Ancient Worm Disease Could Be Eradicated Within Two Years, UN Agency Reports 2Health News:Computer Based Therapy For Depression 2
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... Hemostats First Stop absorbable collagen hemostat. FirstStop ... superior handling and removal characteristics. It can ... to fit the wound. FirstStop products are ... be peeled away after hemostasis is achieved. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: